These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9704431)

  • 1. Risk management in blood transfusion services.
    Whyte G
    Vox Sang; 1998; 74 Suppl 2():105-9. PubMed ID: 9704431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.
    O'Brien SF; Yi QL; Fan W; Scalia V; Kleinman SH; Vamvakas EC
    Transfusion; 2007 Feb; 47(2):316-25. PubMed ID: 17302779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.
    Chiavetta JA; Escobar M; Newman A; He Y; Driezen P; Deeks S; Hone DE; O'Brien SF; Sher G
    CMAJ; 2003 Oct; 169(8):767-73. PubMed ID: 14557314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organizational changes in Canada.
    Décary F
    Vox Sang; 1998; 74 Suppl 2():527-9. PubMed ID: 9704494
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.
    Seed CR; Cheng A; Ismay SL; Bolton WV; Kiely P; Cobain TJ; Keller AJ;
    Transfusion; 2002 Oct; 42(10):1365-72. PubMed ID: 12423522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.
    Seed CR; Kiely P; Keller AJ
    Intern Med J; 2005 Oct; 35(10):592-8. PubMed ID: 16207258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Transfusion safety].
    Aprili G
    Haematologica; 1991 Jun; 76 Suppl 3():385-94. PubMed ID: 1752537
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing.
    Busch MP
    Vox Sang; 1998; 74 Suppl 2():147-54. PubMed ID: 9704438
    [No Abstract]   [Full Text] [Related]  

  • 10. [Safe blood in the absence of viral infections due to HBV, HCV and HIV in serological window period in donors].
    Contreras AM; Reta CB; Torres O; Celis A; Domínguez J
    Salud Publica Mex; 2011; 53 Suppl 1():S13-8. PubMed ID: 21877067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of transfusion-transmitted infections in sub-Saharan Africa.
    Jayaraman S; Chalabi Z; Perel P; Guerriero C; Roberts I
    Transfusion; 2010 Feb; 50(2):433-42. PubMed ID: 19843290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.
    Weusten JJ; van Drimmelen HA; Lelie PN
    Transfusion; 2002 May; 42(5):537-48. PubMed ID: 12084161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy.
    Gonzalez M; Règine V; Piccinini V; Vulcano F; Giampaolo A; Hassan HJ
    Transfusion; 2005 Oct; 45(10):1670-5. PubMed ID: 16181219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS).
    Glynn SA; Kleinman SH; Schreiber GB; Busch MP; Wright DJ; Smith JW; Nass CC; Williams AE
    JAMA; 2000 Jul; 284(2):229-35. PubMed ID: 10889598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romanian blood donors screening: is it really necessary and/or mandatory?
    Hâţu G; Brumboiu MI; Gorgan IN; Bocşan IS
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(3):741-6. PubMed ID: 24502043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study.
    Farshadpour F; Taherkhani R; Tajbakhsh S; Gholizadeh Tangestani M; Hajiani G; Sharifi N; Taherkhani S; Nejadbolkheyr A
    PLoS One; 2016; 11(6):e0157615. PubMed ID: 27309959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia.
    El-Hazmi MM
    Saudi Med J; 2004 Jan; 25(1):26-33. PubMed ID: 14758374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001.
    Soldan K; Barbara JA; Ramsay ME; Hall AJ
    Vox Sang; 2003 May; 84(4):274-86. PubMed ID: 12757501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services.
    O'Brien SF; Yi QL; Fan W; Scalia V; Fearon MA; Allain JP
    Vox Sang; 2012 Jul; 103(1):83-6. PubMed ID: 22289147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence of transfusion transmitted infection among blood donors at Jijiga blood bank, Eastern Ethiopia: retrospective 4 years study.
    Mohammed Y; Bekele A
    BMC Res Notes; 2016 Feb; 9():129. PubMed ID: 26922241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.